Stay updated on Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial

Sign up to get notified when there's something new on the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:38:10.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the evaluation of the effectiveness and safety of oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC). This change may be significant for individuals monitoring medical and healthcare-related publications and documentation.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:35.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying key inclusion and exclusion criteria for potential participants.
    Difference
    13%
    Check dated 2024-05-22T21:30:48.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:18:35.000Z thumbnail image

Stay in the know with updates to Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page.